Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18527536 | 0.92 | EGFR (0.51) | EGFRFGFR2FGFR1KDRJAK3 | |
| SCHEMBL18527542 | 0.92 | EGFR (0.51) | EGFRFGFR2FGFR1KDRJAK3 | |
| SCHEMBL18527541 | 0.92 | EGFR (0.51) | EGFRFGFR2FGFR1KDRJAK3 | |
| SCHEMBL18527548 | 0.91 | EGFR (0.49) | EGFRFGFR2FGFR1KDRJAK3 | |
| SCHEMBL16513994 | 0.89 | EGFR (0.63) | EGFRFGFR2FGFR1KDRJAK3 | |
| SCHEMBL18527529 | 0.84 | FGFR1 (0.57) | EGFRFGFR2FGFR1KDRJAK3 | |
| SCHEMBL16514989 | 0.84 | EGFR (0.66) | EGFRFGFR2FGFR1KDRJAK3 | |
| SCHEMBL16514436 | 0.81 | EGFR (0.62) | EGFRFGFR2FGFR1KDRJAK3 | |
| SCHEMBL16514550 | 0.80 | EGFR (0.61) | EGFRFGFR1KDRJAK3JAK2 | |
| SCHEMBL16513747 | 0.80 | EGFR (0.61) | EGFRFGFR2FGFR1KDRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CDK2, MAP3K6, MAP3K2 | EGFR 555/4885FGFR2 540/4885FGFR1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.